Market Overview - The personal care products sector experienced a decline of 0.29% on October 20, with Dengkang Oral Care leading the drop [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Key stocks in the personal care sector showed varied performance, with Jeya Co. rising by 3.83% to a closing price of 34.72, and Dengkang Oral Care falling by 3.21% to 39.56 [1][2] - Other notable performers included Runben Co. with a 2.97% increase and Liangmian Needle with a 2.87% increase [1][2] Trading Volume and Value - Jeya Co. had a trading volume of 31,000 shares and a transaction value of 108 million yuan, while Dengkang Oral Care had a trading volume of 25,900 shares and a transaction value of 104 million yuan [1][2] Capital Flow - The personal care products sector saw a net inflow of 24.78 million yuan from institutional investors, while retail investors experienced a net outflow of 11.31 million yuan [2][3] - Major stocks like Liangmian Needle had a net inflow of 16.20 million yuan from institutional investors, while Dengkang Oral Care had a net inflow of 4.53 million yuan [3]

Market Overview - The personal care products sector experienced a decline of 1.51% on October 17, with Baiya Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable stock performances included: - Dengkang Oral Care (001328) closed at 40.87, up 1.67% with a trading volume of 24,700 shares and a turnover of 101 million yuan [1] - Yanjing Co., Ltd. (300658) closed at 8.18, up 1.36% with a trading volume of 161,700 shares and a turnover of 132 million yuan [1] - Beijia Clean (603059) closed at 34.10, up 1.25% with a trading volume of 32,100 shares and a turnover of 109 million yuan [1] - However, major declines were seen in companies like Huayue Nursing (605009), which closed at 33.18, down 1.83% [2] Capital Flow Analysis - The personal care products sector saw a net outflow of 15.88 million yuan from institutional investors and 61.87 million yuan from retail investors, while individual investors contributed a net inflow of 77.74 million yuan [2] - Detailed capital flow for specific stocks showed: - Runben Co., Ltd. (603193) had a net inflow of 8.22 million yuan from institutional investors but a net outflow of 9.27 million yuan from retail investors [3] - Beijia Clean (603059) experienced a net inflow of 4.71 million yuan from institutional investors but a net outflow of 8.99 million yuan from retail investors [3] - Major outflows were noted for Juyuan Co., Ltd. (003006), with a net outflow of 2.70 million yuan from institutional investors [3]

Market Overview - The personal care products sector increased by 1.26% on October 15, with Dengkang Oral leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Dengkang Oral (001328) closed at 40.60, with a rise of 6.53% and a trading volume of 47,800 shares, totaling a transaction value of 191 million [1] - Reliable Co. (301009) saw a closing price of 13.92, up 3.49%, with a trading volume of 68,500 shares [1] - HaoYue Care (6005009) closed at 34.17, increasing by 2.67% with a trading volume of 34,200 shares [1] - Other notable performances include Liangmian Needle (600249) at 6.10 (+2.52%) and Baiya Co. (003006) at 25.03 (+2.33%) [1] Capital Flow - The personal care products sector experienced a net inflow of 23.62 million from institutional investors, while retail investors saw a net outflow of 33.67 million [2][3] - The main capital inflow was led by Baiya Co. (003006) with 12.07 million, followed by Liangmian Needle (600249) with 10.93 million [3] - Conversely, the largest outflow was from Reliable Co. (301009) with a net outflow of 5.22 million [3]

（文章来源：证券日报） 证券日报网讯 10月14日晚间，可靠股份发布公告称，公司及全资子公司不存在对合并报表外单位提供 担保，不存在逾期对外担保、涉及诉讼的担保以及因担保被判决败诉而应承担损失的情况。 ...

证券代码：301009 证券简称：可靠股份 公告编号：2025-037 杭州可靠护理用品股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 杭州可靠护理用品股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开了第五届董事会第九次会议和第五届监事会第八次会议、2025 年 5 月 30 日召开了 2024 年度股东大会，审议通过了《关于为全资子公司提供担保的议案》， 同意公司为可靠福祉（杭州）科技有限公司（以下简称"可靠福祉"）、杭州可 睿护理用品销售有限公司分别提供额度不超过人民币 10,000 万元（含本数）、 5,000 万元（含本数）的授信担保，该担保额度使用有效期为股东大会审议通过 之日起十二个月内。在上述使用期限及额度范围内，相关担保额度可循环使用， 并授权公司管理层在使用期限及额度范围内行使具体决策权。具体内容详见公司 于 2025 年 4 月 28 日在巨潮资讯网披露的《关于为全资子公司提供担保的公告》 （公告编号：2025-014）。 法定代表人：金利伟 二、担保 ...

Market Overview - The personal care products sector experienced a slight decline of 0.06% on October 14, with Yanjiang Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Key stocks in the personal care sector showed varied performance, with Jieya Co., Ltd. increasing by 5.08% to a closing price of 35.18 [1] - Other notable performers included Zhongshun Jiesang, which rose by 0.83% to 8.50, and Wanjian Medical, which increased by 0.52% to 38.73 [1] - Conversely, Yanjiang Co., Ltd. saw a significant decline of 5.68%, closing at 8.64 [2] Trading Volume and Value - Jieya Co., Ltd. had a trading volume of 31,700 hands and a transaction value of approximately 108 million yuan [1] - Zhongshun Jiesang recorded a trading volume of 148,600 hands with a transaction value of about 126 million yuan [1] - The overall personal care products sector saw a net outflow of 24.89 million yuan from main funds, while retail investors contributed a net inflow of 20.18 million yuan [2][3] Fund Flow Analysis - Wanjian Medical attracted a net inflow of 14.47 million yuan from main funds, representing 7.86% of its total [3] - Jieya Co., Ltd. also saw a net inflow of 11.52 million yuan from main funds, accounting for 10.70% [3] - In contrast, Yanjiang Co., Ltd. experienced a net outflow of 5.14 million yuan from main funds, indicating a negative sentiment [3]

Market Overview - The personal care products sector experienced a decline of 1.01% on October 13, with Yanjiang Co. leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the personal care sector included: - Beijiajie (603059) with a closing price of 36.07, up 2.53% [1] - Dengkang Oral (001328) at 38.76, up 1.84% [1] - Yiyi Co. (001206) at 34.85, up 1.54% [1] - Major decliners included: - Yanjiang Co. (300658) at 9.16, down 3.68% [2] - Runben Co. (603193) at 27.25, down 2.71% [2] - Baia Co. (003006) at 24.68, down 2.64% [2] Capital Flow Analysis - The personal care products sector saw a net outflow of 30.35 million yuan from institutional investors, while retail investors had a net inflow of 54.37 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Zhongshun Jiesang (002511) had a net inflow of 11.76 million yuan from institutional investors [3] - Mengyue Nursing (605009) saw a net inflow of 8.81 million yuan from institutional investors [3] - Baia Co. (003006) had a net outflow of 7.67 million yuan from institutional investors [3]

（文/罗叶馨梅）近日，企查查信息显示，华致联合（德阳）科技有限公司近日成立，注册资本2000万元，经营范围包括集成电路芯片及产品制造、设计、 销售等多个领域。股权信息显示，该公司由致尚科技（301009.SZ）等共同持股。 致尚科技表示，参与设立新公司有助于公司进一步拓展半导体及集成电路相关业务布局，强化产业链协同效应，提升技术创新能力与市场竞争力。该项目的 推进预计将为公司带来新的业务增长点。 业内分析认为，随着国内芯片制造及设计能力的快速发展，相关企业正积极加大在集成电路领域的布局。致尚科技等企业通过合资方式切入，有助于推动区 域半导体产业集群建设，抢占行业发展机遇。 市场人士指出，当前集成电路产业已成为国家重点支持方向，政策、资本与技术多方推动下，相关企业加速整合与创新。致尚科技的此项投资动作，或将成 为其长期战略升级的重要一环。（校对/秋贤） | 统一社会信用代码 | 91510600MAEWQY3993 | 企业名称 | 华致联合（德阳）科技有限公司 | | | | --- | --- | --- | --- | --- | --- | | 法定代表人 | 存续(在营、开业、在册) 成立日期 邓轩满 ...

Core Insights - The personal care products sector experienced a 0.58% increase on October 9, with Beijia leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance Summary - Beijia (603059) closed at 34.19, up 2.80% with a trading volume of 26,600 and a transaction value of 90.90 million [1] - Yiyi Co. (001206) closed at 31.20, up 2.70% with a trading volume of 49,000 and a transaction value of 150 million [1] - Yanjing Co. (300658) closed at 9.32, up 2.42% with a trading volume of 241,600 and a transaction value of 229 million [1] - Reliable Co. (301009) closed at 13.63, up 2.10% with a trading volume of 31,700 and a transaction value of 42.76 million [1] - Stable Medical (300888) closed at 38.81, up 1.33% with a trading volume of 45,700 and a transaction value of 176 million [1] - Other notable stocks include Liangmian Needle (600249) at 5.91, up 0.85%, and Runben Co. (603193) at 28.03, up 0.07% [1] Capital Flow Analysis - The personal care products sector saw a net inflow of 22.62 million from institutional investors, while retail investors experienced a net outflow of 19.11 million [2] - Major stocks with significant net inflows include Stable Medical (300888) with 10.81 million and Dengkang Oral (001328) with 8.52 million [3] - Conversely, stocks like Beijia (603059) and Liangmian Needle (600249) experienced net outflows of 4.81 million and 0.25 million respectively [3]

Core Insights - The EGFR x HER3 dual antibody ADC iza-bren (BL-B01D1) developed by Bai Li Tianheng has received multiple significant approvals and recognitions in September 2023, indicating its potential as a breakthrough treatment in oncology [1][2][3] Group 1: Regulatory Approvals - On September 5, 2023, iza-bren was officially included in the priority review list by the National Medical Products Administration (NMPA) for treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed at least two lines of chemotherapy [1] - On September 10, 2023, iza-bren was listed as a breakthrough therapy for treating platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [2] - On September 17, 2023, iza-bren was proposed for inclusion as a breakthrough therapy for locally advanced or metastatic urothelial carcinoma patients who have failed prior platinum-based chemotherapy and PD-1/PD-L1 inhibitors, marking its seventh breakthrough therapy designation in China [2] Group 2: Clinical Research Achievements - Two studies of iza-bren were selected for the official news release program of the 2025 World Lung Cancer Conference (WCLC), showcasing the highest-rated research outcomes [1] - The Phase II study of iza-bren combined with Osimertinib for treating advanced or metastatic EGFR-mutant non-small cell lung cancer reported an overall response rate (ORR) of 100%, marking it as the first treatment regimen globally to achieve such a result [1] - In October 2023, iza-bren's first registered Phase III clinical trial results will be presented at the European Society for Medical Oncology (ESMO) annual meeting, with the results included in the prestigious Late-breaking Abstract (LBA) session [3] Group 3: Collaborative Efforts - Tai Mei Medical Technology has provided various digital clinical research solutions for the series of studies related to iza-bren, supporting the advancement of Chinese innovative drugs on the global stage [3] - The independent efficacy evaluation of the Phase II study of iza-bren was efficiently conducted using AI and digital systems, demonstrating the capabilities of Tai Mei Medical Technology in supporting clinical research [3]